<DOC>
	<DOCNO>NCT01588678</DOCNO>
	<brief_summary>DS-3078a evaluate single agent subject advance solid tumor malignancy lymphomas refractory standard treatment standard treatment available .</brief_summary>
	<brief_title>A Open-Label , Multiple Ascending Dose Study DS-3078a , Oral TORC1/2 Kinase Inhibitor , Subjects With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>This Phase 1 , open-label study DS-3078a ass safety tolerability , identify maximum tolerate dose ( MTD ) tentative recommend phase 2 dose ( RP2D ) , assess pharmacokinetic pharmacodynamic property subject advanced solid tumor malignancy lymphomas . The study include 2 part : Dose Escalation Dose Expansion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>A pathologically cytologically document advanced solid tumor lymphoma relapse refractory standard treatment standard treatment available . Men woman &gt; =18 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Have adequate bone marrow function , define : Platelet count &gt; =100 x 10^9/L solid tumor &gt; =75 x 10^9/L lymphoma , Hemoglobin level &gt; =9.0 g/dL , ANC &gt; =1.5 x 10^9/L solid tumor &gt; =1.0 x 10^9/L lymphoma . Have adequate renal function , define : Creatinine clearance &gt; =60 mL/min , creatinine = &lt; 1.5 x ULN . Have adequate hepatic function , define : AST/ALT level = &lt; 3 x ULN ( = &lt; 5 x ULN liver metastasis present ) Bilirubin = &lt; 1.5 x ULN . Have adequate blood clot function , define prothrombin time activate partial thromboplastin time = &lt; 1.5 x ULN . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date Institutional Review Board/Ethics Committeeapproved inform consent form ( include Health Insurance Portability Accountability Act authorization , applicable ) performance study specific procedure test . For Part 2 A pathologically cytologically document advanced solid tumor nonHodgkin lymphoma , measurable disease base RECIST 1.1 revise IWG criterion , refractory standard treatment . The solid tumor type include study follow kind mTOR signal frequently activate : endometrial , prostate , breast , gastric , cervical , ovarian , neuroendocrine cancer , softtissue sarcoma , squamous cell NSCLC , renal cell carcinoma tumor type approve Sponsor . Agree undergo pre posttreatment tumor biopsy . History primary central nervous system malignancy Gastrointestinal disease could affect absorption DS3078a opinion Investigator Subjects fast glucose &gt; 126 mg/dL ( &gt; 7 mmol/L ) History diabetes mellitus ( type 1 2 ) glycosylated hemoglobin &gt; 7.0 % screen Positive test hepatitis B surface antigen hepatitis C antibody Recipient live vaccine within 1 month study drug treatment Use chronic systemic corticosteroid ( use nasal inhale steroid permit ) Subjects require daily supplemental oxygen Recipient allogenic stem cell bone marrow transplant Presence concomitant medical condition would increase risk toxicity , opinion Investigator Sponsor Clinically active brain metastasis , define untreated symptomatic , require therapy steroid anticonvulsant control associate symptom . Has unresolved toxicity previous anticancer therapy , define toxicity ( alopecia ) yet resolve NCICTCAE v4 grade = &lt; 1 baseline . Systemic treatment anticancer therapy , antibodybased therapy , retinoid therapy , hormonal therapy within 3 week study drug treatment ; treatment nitrosoureas mitomycin C within 6 week study drug treatment ; treatment smallmolecule target agent within 2 week 5 halflives study drug treatment , whichever longer . Therapeutic radiation major surgery within 4 week study drug treatment palliative radiation therapy within 2 week study drug treatment Participation clinical study within 3 week ( 2 week 5 halflives , whichever longer , smallmolecule target agent ) study drug treatment , current participation investigational procedure Concomitant treatment strong inhibitor inducer cytochrome P450 3A4 P glycoprotein Less 1 week since use systemically act drug increase gastric pH , H2blockers proton pump inhibitor . Antacids avoid within 48 hour first dose DS 3078a Prolongation correct QT interval Fridericia 's method ( QTcF ) rest , mean QTcF interval &gt; 450 msec base triplicate electrocardiogram ( ECG ) Pregnant breastfeed Substance abuse medical , psychological , social condition , opinion Investigator , may interfere subject 's participation clinical study evaluation clinical study result For Part 2 Subjects prior treatment mTOR catalytic site inhibitor dual PI3K/mTOR inhibitor ( include , limited , OSI027 , INK128 , ADZ8055 , AZD2014 , WYE12513 , PP242 , BEZ235 , DS7423 , XL765 , GDC0980 , SF1126 , GSK2126458 , PF4691502 , PF05212384 ) disqualify enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>endometrial</keyword>
	<keyword>prostate</keyword>
	<keyword>breast</keyword>
	<keyword>gastric</keyword>
	<keyword>cervical</keyword>
	<keyword>ovarian</keyword>
	<keyword>neuroendocrine cancer</keyword>
	<keyword>soft-tissue sarcoma</keyword>
	<keyword>squamous cell NSCLC</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
</DOC>